A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)

Prior treatment

• Participants are excluded from the study if they meet any of the following criteria:
  • Participants who are unable to understand all implications of study participation.
  • Participants who have contraindications for treatment with tislelizumab in the investigator's opinion or have any contraindication as listed in the SmPC of tislelizumab.
  • Participants who are deemed ineligible according to the investigator's opinion and the SmPC of tislelizumab.

• Participants are eligible to be included in the study only if they meet all the following criteria:
  • Participants or their legal representative must sign written inform consent form (ICF)
  • Participants receive tislelizumab as part of routine clinical practice as determined by the treating physician per standard of care and in accordance with the SmPC, within the approved indications in the 4 cohorts described.
  • Note: The decision to treat the patient with a tislelizumab-based regimen, as per its authorized indication, must have been made by the treating physician prior to and independent of the patient's consideration for participation in this study.